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A B S T R A C T
Nephrotoxicity is an important limitation to the clinical use of many drugs and contrast media. Drug ne-
phrotoxicity occurs in acute, subacute and chronic manifestations ranging from glomerular, tubular, vascular
and immunological phenotypes to acute kidney injury. Pre-emptive risk assessment of drug nephrotoxicity poses
an urgent need of precision medicine to optimize pharmacological therapies and interventional procedures in-
volving nephrotoxic products in a preventive and personalized manner. Biomarkers of risk have been identified
in animal models, and risk scores have been proposed, whose clinical use is abated by their reduced applicability
to specific etiological models or clinical circumstances. However, our present data suggest that the urinary level
of transferrin may be indicative of risk of renal damage, where risk is induced by subclinical tubular alterations
regardless of etiology. In fact, urinary transferrin pre-emptively correlates with the subsequent renal damage in
animal models in which risk has been induced by drugs and toxins affecting the renal tubules (i.e. cisplatin,
gentamicin and uranyl nitrate); whereas transferrin shows no relation with the risk posed by a drug affecting
renal hemodynamics (i.e. cyclosporine A). Our experiments also show that transferrin increases in the urine in
the risk state (i.e. prior to the damage) precisely as a consequence of reduced tubular reabsorption. Finally,
urinary transferrin pre-emptively identifies subpopulations of oncological and cardiac patients at risk of ne-
phrotoxicity. In perspective, urinary transferrin might be further explored as a wider biomarker of an important
mechanism of predisposition to renal damage induced by insults causing subclinical tubular alterations.
1. Introduction
Drug nephrotoxicity is a most serious health problem [1,2] and an
important cause of failure along the drug discovery process [3].
Members of many drugs families including antibiotics, antineoplastics,
antivirals, immunosupressors, proton pump inhibitors, analgesics, an-
tihypertensives and others; radiological iodinated contrast media; and
22 % of the 100 most used drugs in intensive care are nephrotoxic [4].
Drug nephrotoxicity shows a wide range of acute, subacute and chronic
manifestations depending on the mechanisms, dosage, and patient
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characteristics and comorbidities, reflecting damage or functional al-
terations to different nephron segments and systemic and renal hemo-
dynamics. The clinical manifestations of nephrotoxicity often go un-
recognized, especially during short exposures, which hinders diagnosis,
severity assessment and evaluation of immediate, medium- and long-
term consequences. Recently, an international initiative has generated a
standard consensus definition of drug nephrotoxicity [5]. Specifically,
several phenotypes of drug nephrotoxicity were recognized, namely
acute kidney injury (AKI) due to acute tubular necrosis (ATN), tubular
disorders, glomerular disorders, nephrolithiasis and combinations
thereof. In fact, these latter may be independent nephrotoxic manifes-
tations, pose a subclinical degree of AKI, or even be the cause and
underlie an AKI. Additional phenotypes, not included in this definition,
are hemodynamic AKI [2], nephritis [6] and vascular and micro-
vascular angiopathies [7].
AKI is a syndrome of sudden renal excretory dysfunction with ser-
ious health consequences and high cost [8], consuming 1 % of total
health budget [9] and 5 % of hospital expenditure [10,11]. According
to international scales (i.e. RIFLE, AKIN and KDIGO), AKI is diagnosed
by increments in plasma creatinine (Crpl) [12]. However, Crpl may not
be sufficiently sensitive to detect acute nephrotoxicity [13], because
significant damage must occur for Crpl to increase. A Crpl insensitivity
window results from the recruitment of renal functional reserve and
from an increased creatinine secretion [14]. More sensitive and earlier
biomarkers are under development for the detection of subclinical AKI,
i.e. with normal Crpl [15,16], including neutrophil gelatinase-asso-
ciated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), tissue in-
hibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor
binding protein-7 (IGFBP-7) [17], and N-acetylglucosaminidase (NAG)
[18]. Tubular disorders encompass alterations in tubular transport
leading to mishandling of phosphate, glucose, magnesium, potassium,
proteins or water [5].
Following this international definition, a 6R framework (risk, re-
cognition, response, renal support, rehabilitation and research) has
been proposed to identify and manage drug induced renal damage,
where early and sensitive diagnosis is critical for effective patient triage
and clinical handling, and for optimal outcome [1]. In the line of risk
assessment, acquired predisposition to renal damage has been described
as a distinct but complementary concept to early and subclinical da-
mage. Predisposition is a condition of increased risk of suffering renal
damage, hitherto undetectable at the clinical level. Only population risk
factors have been identified, which include age, previous renal func-
tion, diabetes, volemia, and others [2]. However, stratification of pa-
tients according to their individual risk, before being exposed to kidney-
injuring medical or environmental conditions may open a new concept
to handle AKI from a truly preventive and personalized manner, and
also for monitoring AKI risk in the community. This concept has been
mainly developed hitherto in animal models of nephrotoxicity.
[19–21], in which animals are treated with subtoxic regimes of dif-
ferent nephrotoxic drugs. These treatments render animals, compared
to untreated controls, more susceptible to developing an AKI; so that
when they are subject to a second aggression (completely innocuous for
controls), an overt AKI (i.e. acute tubular necrosis) occurs.
Biomarkers of predisposition have been identified in these animal
models, which include t-gelsolin, ganglioside M2 activator protein
(GM2AP), fumarylacetoacetase (FAA), and others. However, clinical
application has been limited by their specificity for individual predis-
posing agents. For instance, no common mechanism of predisposition
has been identified, and no universal marker of increased risk is hi-
therto known. In fact, patient-stratifying scores have been developed,
but only with ad hoc and limited applicability to specific clinical sce-
narios [22]. In this article we show evidence suggesting that urinary
transferrin might be a wider biomarker of predisposition to renal da-
mage induced by insults causing subclinical tubular alterations, which
pre-emptively identifies a subpopulation of oncological and cardiac
patients at risk of nephrotoxicity.
2. Material and methods
Except where otherwise indicated, all reagents were purchased from
Sigma–Aldrich (Madrid, Spain).
2.1. Animal models and experimental protocols
Male Wistar rats (200−250 g) were maintained under controlled
conditions within the University of Salamanca Animal House facility,
with free access to water and standard chow. All procedures were ap-
proved by the Bioethics Committee of the University of Salamanca and
the Consejería de Agricultura y Ganadería of the Junta de Castilla y
León. Animals were handled according to the guidelines of the
Fig. 1. Schematic representation of the ex-
perimental groups. White syringes symbolize
intraperitoneal administration, and black syr-
inges subcutaneous administration. Bottles re-
present oral administration in drinking water.
CP, cisplatin; 2, 2.5 and 3 refers to the dose
(mg/kg); G, gentamicin (50mg/kg); S, saline;
CsA, cyclosporine (15mg/kg); UN, uranyl ni-
trate (5.4 g/L).
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European Community Council Directive 2010/63/UE, and to the cur-
rent Spanish legislation for experimental animal use and care, RD 53/
2013. At specific time points, rats were placed in individual metabolic
cages for urine collection.
Rats were divided into the following groups (n=4 per group)
(Fig. 1): CP2, CP2.5 and CP3 groups, that received an intraperitoneal
(i.p.) injection of a sub-nephrotoxic dose of cisplatin (2, 2.5 and 3mg/
kg, respectively); CP2+G, CP2.5+G and CP3+G groups, which re-
ceived a sub-nephrotoxic dose of cisplatin (as above), followed by a
sub-nephrotoxic dose of gentamicin (50mg/kg i.p. for 6 days from day
2), as the second nephrotoxic agent; G group, that received gentamicin
(50mg/kg i.p.) for 6 days; CsA+G, which received a sub-nephrotoxic
dose (15mg/kg) of subcutaneous (s.c.) cyclosporine for 7 days, and
gentamicin (50mg/kg i.p.) for 6 days from day 7; G+CsA, which re-
ceived gentamicin (50mg/kg i.p.) for 6 days, and cyclosporine (15mg/
kg s.c.) for 7 days from day 6; UN+G, which received uranyl nitrate
(5.4 g/L in the drinking water) for 21 weeks, and gentamicin (50mg/kg
i.p.) for 4 days from week 21; and their respective Control groups,
which received the vehicle (i.e. saline). 24 h urine was collected in
metabolic cages, cleared by centrifugation and stored at -80 °C. Blood
samples (200 μL) were obtained in heparinized capillaries from a small
incision in the tail tip. Plasma was separated by centrifugation and kept
at -80 °C. At the end, rats were anesthetized, blood was collected and
the kidneys dissected and fixed in 3.7 % para-formaldehyde for histo-
logical studies.
In order to establish whether transferrin is reabsorbed in the prox-
imal tubule under physiological conditions, sodium maleate was ad-
ministered at a dose of 400mg/kg intravenously to 6 healthy rats to
cause decoupling of their tubular transport systems. Urine samples were
directly collected from the bladder, before and after administration of
maleate.
2.2. In situ renal perfusion
At the end of the experimental protocol of treatment with cisplatin,
some rats were anesthetized and an extracorporeal circuit for kidney
perfusion was set up, as described elsewhere [23]. Briefly, the renal
artery and vein of the left kidney and the urinary bladder were can-
nulated. Renal perfusion was interrupted during surgery for a maximum
of one minute. Oxygenated and warm (37 °C) Krebs-dextran [40 g/L of
dextran (molecular weight 64−76 kDa) in Krebs solution (118.3 mM
NaCl, 4.7 mM KCl, 1.8mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4,
25 mM NaHCO3, 0.026mM EDTA, 11.1 glucose, pH=7.4)] was per-
fused through the renal artery at 3mL/min. Urine fractions were col-
lected from a catheter placed in the urinary bladder, starting before
initiating the perfusion with Krebs (when the kidney was still perfused
with blood), and for 60min after initiating Krebs perfusion. As a control
of these perfusion experiments, in order to exclude a potential artefact
derived from surgery or other experimental maneuvers, kidneys were
also perfused in situ with blood from the carotid artery. For this pur-
pose, the artery, vein and ureter of the left kidney were ligated as
above. A catheter was placed in the left carotid artery and connected
directly to the renal artery. Urine was collected as above.
2.3. Renal function assessment in animal models
Plasma and urine creatinine were measured using a commercial kit
based on the Jaffe method [24] (QuantiChrom Creatinine Assay Kit,
BioAssay Systems, Hayward, CA, USA). Plasma urea was determined
using a commercial kit based on the Jung method [25] (QuantiChrom
Urea Assay Kit, BioAssay Systems, Hayward, CA, USA). Creatinine
clearance (CLcr) was calculated using the formula: CLcr=Crur x UF/Crpl;
where Cru corresponds to urinary concentration of creatinine, UF is
urine flow and Crpl is plasma concentration of creatinine. Proteinuria
was measured with the Bradford assay [26].
2.4. Renal histology in animal models
Tissue was fixed in 3.7 % para-formaldehyde and embedded in
paraffin; 5 μm tissue sections were stained with hematoxylin and eosin.
Photographs were taken under an Olympus BX51 microscope connected
to an Olympus DP70 color, digital camera (Olympus, Madrid, Spain).
2.5. Patients and clinical protocol
Two observational studies were conducted to pre-emptively eval-
uate the risk of renal damage in two, non-related clinical scenarios.
Both were proof-of-concept studies rooted in routine clinical practice,
and not ad-hoc designed clinical trials, and followed the principles es-
tablished in the Declaration of Helsinki (World Medical Assembly), the
Council of Europe Convention on Human Rights and Biomedicine, the
UNESCO Universal Declaration on the Human Genome and Human
Rights, the requirements established in the Spanish legislation in the
field of biomedical research, personal data protection and bioethics; as
well as the provisions of the Law 14/2007, of July 3rd, of Biomedical
Research; and RD 53/2013, of February1st. Both studies were approved
by the Ethical Committee for Clinical Investigation and all patients
provided written informed consent. In both studies exclusion criteria
were any diseases or clinical conditions that, in the opinion of the in-
vestigators, would interfere with the study evaluation.
2.5.1. Study 1: oncology patients treated with platinated antineoplastics
This study was conducted during 2015 and 2016 with patients from
the Medical Oncology Service of the University Hospital of Salamanca
(Salamanca, Spain). Patients diagnosed with various types of cancer
and prescribed cisplatin or carboplatin, were included. Blood and urine
samples were collected immediately before and 72 h after the admin-
istration of each chemotherapy cycle including cisplatin or carboplatin.
Platinated antineoplastics are effective chemotherapeutic drugs
[27–29] commonly used to treat a variety of solid cancers, including
head and neck, oesophageal, non-small cell lung, testicular, ovarian,
breast, cervical and bladder cancer [30]. Their dosage and effectiveness
are limited by their nephrotoxicity, which occurs in 25–35 % of adult
[31] and in 70 % of paediatric [32] patients, and exhibits a tubular
phenotype, ranging from electrolytic disturbances derived from im-
paired tubular handling (i.e. most typically hypomagnesemia and hy-
pokalemia), to ATN and AKI (with rising plasma creatinine and urea
levels) [33–36]. Accordingly, evidence of nephrotoxicity was defined as
detection of abnormalities after the administration of the platinum-
based antineoplastic in at least two of the following plasma analytes
simultaneously, defined as: a) an increase in plasma creatinine over the
normal range; b) an increase in plasma urea of over the normal range;
c) a decrease in calcemia below the normal range; and d) a decrease in
magnesemia below the normal range. Normal ranges for these para-
meters are shown in Table 1 caption. Patients were divided into two
groups: (i) Cases, i.e. patients who underwent alteration of at least two
of these four blood parameters evaluated at some point during their
treatment; and (ii) Controls, i.e. patients who did not suffer alterations
in those parameters after at least three cycles of chemotherapy. Plasma
creatinine, urea, calcium and magnesium were obtained from routine
blood tests. Basal urine and urine previous to the moment of peak al-
teration of these blood parameters were selected for biomarker as-
sessment.
2.5.2. Study 2: cardiology patients exposed to iodinated contrast media
Iodinated contrast media cause a specific type of acute kidney injury
known as contrast-induced nephropathy (CIN), defined as an increase
in the plasma creatinine concentration greater than 0.5mg/dl, or 25–50
% of the baseline value, within the first 5 days after the administration
of the contrast medium (in the absence of other causes that justify it,
such as surgery, other nephrotoxic drugs, hypovolemia, etc.) [37,38].
The incidence of CIN in patients undergoing percutaneous coronary
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interventions can reach 25 % [39,40] or 50 % in high-risk patients
[41,42]. CIN is the third most frequent cause of acute renal failure in
hospitalized patients [43].
This study was conducted from 2015 to 2017 with patients from the
Cardiology Department of the University Hospital of Salamanca
(Salamanca, Spain). Patients undergoing cardiac catheterization invol-
ving administration of iodinated contrast media (iohexol or iodixanol)
were included. Blood and urine samples were collected immediately
before the administration of the contrast media, and daily after until
discharge. Patients were classified as Cases or Controls if subsequently
underwent CIN or not, respectively. Accordingly, (i) Cases were pa-
tients who suffered CIN; and (ii) Controls were patients who did not
suffer CIN. Plasma creatinine and urea were obtained from routine
blood tests, both at baseline and during follow-up. Basal urine was se-
lected for biomarker assessment.
2.6. Quantification of biomarkers of early kidney damage in rat and human
urine samples
NAG activity was quantified using a commercial kit [N-Acetyl-β-D-
glucosaminidase (NAG) assay kit, Diazyme, Poway, CA, USA] following
the manufacturer's instructions. NGAL was measured by commercial
ELISAs (Human NGAL ELISA Kit 036CE and Rat NGAL ELISA Kit 046,
BioPorto Diagnostics, Hellerup, Denmark), according to the manu-
facturer’s instructions. Biomarker values in humans were factored by
urinary creatinine concentration, as a means to normalize the effect of
urine concentration.
2.7. Quantification of transferrin in rat and human urine samples
Transferrin was measured by Western blot. Briefly, 21 μL per human
urine sample, or a volume of urine from each rat corresponding to the
same fraction of 24 -h urinary output, were separated by 4–20 % gra-
dient polyacrylamide gel electrophoresis (4-20 % Criterion TGX Stain-
Free Protein Gel, Bio-Rad Laboratories, Hercules, CA, USA).
Immediately, proteins were electrically transferred to an Immun-Blot
PVDF Membrane (Bio-Rad Laboratories, Hercules, CA, USA) and in-
cubated with anti-transferrin antibody (sc-22597, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), followed by horseradish perox-
idase-conjugated secondary antibodies and chemiluminescent detection
(Clarity Western ECL Substrate, Bio-Rad Laboratories, Hercules, CA,
USA) with photographic films (Fujifilm, Tokyo, Japan). Bands were
Table 1
Initial characteristics and pharmacological data of patients included in the study. Values are expressed as mean ± SEM. n.s.: non-significant. Normal value ranges
(mg/dL) for biochemical parameters: 1) Plasma creatinine (0.7–1.2 in males / 0.5-0.9 in females). 2) Plasma urea (16.6–48.5). 3) Calcemia (8.8–10.2 / 8.6–10.0 in
females). 4) Magnesemia (1.6–2.4 in males / 1.6–2.6 in females).
STUDY 1: ONCOLOGY
Anthropometric and pharmacological data
Cases (n=18) Controls (n= 17) p-value
Gender (m/f) 13/5 9/8 n.s.
Age (years) 61.1 ± 1.9 57.1 ± 1.6 n.s.
Weight (kg) 78.1 ± 3.3 71.2 ± 2.7 n.s.
Body Mass Index (kg/
m2)
28.6 ± 1.1 26.4 ± 1.3 n.s.





Cisplatin dose (mg) 107 ± 11 99 ± 13 n.s.
Carboplatin dose (mg) 535 ± 56 625 ± 41 n.s.
Biochemical data








































Anthropometric and pharmacological data
Cases (n=31) Controls (n=122) p-value
Gender (m/f) 22/9 93/29 n.s.
Age (years) 78.0 ± 2.3 72.6 ± 1.2 p= 0.009
Weight (kg) 69.9 ± 2.1 75.6 ± 1.2 p= 0.042
Body Mass Index (kg/m2) 26.4 ± 0.8 27.8 ± 0.4 p= 0.044
Patients treated with iohexol/iodixanol/no data 5/22/4 27/84/11 n.s.
Iohexol dose (mg) 334.6 ± 46.7 263.9 ± 24.1 n.s.
Iodixanol dose (mg) 291.4 ± 23.5 288.7 ± 16.3 n.s.
Biochemical data
Men Women Men Women
Plasma creatinine (mg/dL) 1.39 ± 0.15 1.14 ± 0.26 1.11 ± 0.53 0.89 ± 0.05 n.s.
Plasma urea (mg/dL) 72.75 ± 9.11 56.37 ± 7.19 49.81 ± 2.52 50.42 ± 4.20 Men
p=0.005
Women n.s.
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quantified by densitometry analysis with the Scion Image software
(Frederick, MD, USA). Inter-gel normalization was carried out by re-
ferring band quantification data to the same positive control loaded in
each gel. Transferrin values in humans (arbitrary units, AUs) were
factored by urinary creatinine concentration, as a means to normalize
the effect of urine concentration [44].
2.8. Statistical analysis
Data are presented as the mean ± standard error of the mean
(SEM). Data normal distribution was evaluated using the Kolmogorov-
Smirnov test. After that, an ANOVA with Tukey’s test was performed to
compare preclinical experimental groups; and paired Chi-Square (for
qualitative variables), Student’s t-test or U-Mann-Whitney (for quanti-
tative variables) tests were also used to compare some preclinical re-
sults and to assess differences between Cases and Controls in the clinical
study. In preclinical studies, the correlation between the urinary levels
of each biomarker before the administration of the second nephrotoxic
agent versus the severity (plasma urea and creatinine) of subsequent
AKI was evaluated by the Pearson’s test. In the clinical study, the di-
agnostic capacity of transferrin was evaluated through a Receiver
Operating Characteristic (ROC) curve-based analysis [45]. Statistical
analysis was performed with the IBM SPSS Statistics 20.0 software
(International Business Machines, Armonk, NY, USA). Microsoft Office
Excel 2016 and IBM SPSS Statistics 20.0 were used to create the art-
work and illustrations presented.
3. Results
3.1. Urinary transferrin is a biomarker of predisposition to AKI in specific
animal models of subclinical tubular damage and not in others
Transferrin had been previously identified as a urinary biomarker of
uranium-induced predisposition to AKI [20], but it had not been tested
in other preclinical models, and it was thus unknown whether it was
stimulus-specific. The purpose of this new study was to elucidate
whether urinary transferrin marks a specific process or mechanism of
predisposition to AKI, is thus a common marker of different predis-
posing causes, or at least is a marker of a common mechanism engaged
by different predisposing causes. Figs. 2, 3 and 4 show that renal
function and renal histology become altered only in animals previously
predisposed to AKI by subnephrotoxic regimes of cisplatin, cyclos-
porine, gentamicin and uranyl nitrate (i.e. the different predisposing
agents), and not in non-predisposed animals, when subsequently chal-
lenged by a subnephrotoxic dose of a second toxin (i.e. the triggering
insult). In fact, exposure to only the predisposing agents or to the
triggering insults results, by itself, in no alterations in renal function or
histology. However, when animals were subjected sequentially to both
the predisposing agent and the triggering insult, an overt, intrinsic AKI
ensued, as evidenced functionally by increased plasma creatinine and
urea concentrations and decreased creatinine clearance; and histologi-
cally by ATN, with widespread tubular dilation and degeneration,
massive cell death, tubular casts and inflammatory cell infiltration.
Interestingly, the increase in the urinary transferrin excretion was
higher in animals predisposed to AKI following most subnephrotoxic
Fig. 2. Plasma creatinine and urea levels, creatinine clearance and urinary protein excretion in a rat model of predisposition to AKI by cisplatin. Values are expressed
as the mean ± SEM. a: There was a death before completing the experiment; *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. its corresponding group without
gentamicin; #, p < 0.05; ##, p < 0.01; ###, p < 0.001 vs. G group; &, p < 0.05; &&, p < 0.01; &&&, p < 0.001 vs. Control group. CP, cisplatin; G, genta-
micin.
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regimes (i.e. cisplatin, gentamicin and uranyl nitrate), but not following
cyclosporine, when compared to controls receiving the vehicle instead
(Fig. 5). Of note, urinary transferrin was elevated following adminis-
tration of cisplatin dosages (i.e. 2.5 and 3.0mg/kg) that predispose to
subsequent triggers of AKI, but not following the non-predisposing
dosage (i.e. 2.0 mg/kg) (see Fig. 5 for transferrin values, and Fig. 2 for
evidence of predisposition). Overall, these data strongly link increased
urinary transferrin to acquired predisposition to AKI. Additionally, ur-
inary transferrin predicted the severity of the subsequent AKI developed
upon administration of the triggering agent. Specifically, the increment
in urinary transferrin excretion induced by the predisposing agent
statistically correlates with the severity of renal damage caused by the
triggering insult (Fig. 6). Indeed, the higher the level of transferrin prior
to the administration of the triggering insult, the higher the level of
plasma creatinine and urea reached. Finally, the predictive capacity of
two markers of subtle and subclinical renal damage, i.e. as urinary NAG
and NGAL, was also tested. Table 2 shows that neither marker shows
any positive correlation with the subsequent renal damage.
3.2. Increased urinary excretion of transferrin results from decreased
tubular uptake
In order to unravel the origin and mechanism of the increased levels
of urinary transferrin found in rats predisposed to AKI and, specifically,
whether it was the result of a subclinical tubular alteration that would
corroborate our hypothesis, we used the subclinical cisplatin predis-
position model. The right kidney was ligated and the left kidney was
perfused in situ with a protein-free solution (i.e. Krebs-dextran). Urine
was collected prior to and during Krebs perfusion in rats treated with a
subnephrotoxic dose (3mg/kg) of cisplatin. Fig. 7a shows that trans-
ferrin disappears from the urine of cisplatin-predisposed rats when the
kidney is perfused with Krebs solution. This supports the idea that
Fig. 3. Plasma creatinine and urea levels, creatinine clearance and urinary protein excretion in different rat models of predisposition to AKI. Values are expressed as
the mean ± SEM. *, p < 0.05; **, p < 0.01 vs. Control group. Predisp., predisposition; d, day; w, week; CsA, cyclosporine; G, gentamicin; UN, uranyl nitrate.
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urinary transferrin comes from the blood and not from renal structures.
Furthermore, inhibition of proximal tubule transport with maleate in
control rats resulted in a sustained increase in urinary transferrin
(Fig. 7b). These results support a mechanism of transferrin trafficking to
urine in rats predisposed to AKI, whereby a subclinical defect in its
tubular handling (i.e. probably decreased proximal tubule reabsorp-
tion) results in increased urinary transferrin excretion.
Our results from in situ perfused kidneys, and from the maleate
model suggest that the increased levels of urinary transferrin found in
rats predisposed to AKI result from an altered tubular reabsorption.
3.3. Urinary transferrin pre-emptively identifies oncological patients
subsequently undergoing platinum-based therapy nephrotoxicity and cardiac
patients subsequently suffering contrast-induced nephropathy
The clinical utility of transferrin as a pre-emptive marker of pre-
disposition to, or risk of, kidney damage was evaluated in two groups of
patients: (i) oncological patients who were to be treated with cisplatin
or carboplatin; (ii) patients with heart disease who were to be subject to
a procedure involving the administration of an iodinated contrast
medium. In both cases transferrin was measured before the adminis-
tration of the cytostatic or contrast medium, with the objective of
studying whether its urinary levels were predictive of subsequent renal
damage. Patients were then monitored for evidence of newly developed
nephrotoxicity following treatment. Before treatment, patients are ex-
pected to have a range of baseline, individual risk values depending on
an undetermined mixture of predisposing conditions impossible to
identify (resulting from their individual exposure to predisposing
agents, lifestyle, comorbidities, etc.) and, hitherto impossible to detect
and quantify by existing diagnostic technology.
3.3.1. Study 1: oncology
70 patients initially volunteered, but 35 were excluded (27 died or
withdrew consent; and 8 had abnormal baseline values for two of the
four parameters of nephrotoxicity, including plasma creatinine).
Finally, 35 patients completed the study. Of them, 18 were considered
Cases since they developed new evidence of nephrotoxicity. The other
17 patients showed no evidence of nephrotoxicity, and were labelled as
Fig. 4. Representative images of renal his-
tology in rat models of predisposition to AKI.
Scale bar: 50 μm. CP: cisplatin; CsA: cyclos-
porine; G: gentamicin; UN: uranyl nitrate.
Whereas individual (single) treatments cause
no signs of gross tissue damage, all combina-
tions of predisposing+ triggering factors show
an evident tubular necrosis characterized by
tubule loss and obstruction. Black arrows in-
dicate areas of tubular necrosis with massive
de-epithelialized tubules, and tissue debris.
Yellow arrows show areas of severe tubular
obstruction (with hyaline material). White ar-
rows point at dilated tubules (For interpreta-
tion of the references to colour in this figure
legend, the reader is referred to the web ver-
sion of this article).
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Controls. Their initial anthropometric and pharmacological data are
presented in Table 1.
3.3.2. Study 2: cardiology
Of the 172 patients initially included, 19 voluntarily left the study.
Finally, 153 patients completed the study. Out of them, 31 were con-
sidered Cases, because they developed CIN. The other 122 patients did
not develop CIN and, therefore, they were considered Controls. Their
initial anthropometric and pharmacological data are presented in
Table 1.
As shown in Fig. 8, when measured before the initiation of pla-
tinum-based therapy, the urinary levels of transferrin were significantly
higher in Cases, i.e., in patients who subsequently developed evidence
of nephrotoxicity, than in Controls who did not. ROC curves were ob-
tained for the capacity of urinary transferrin to pre-emptively dis-
criminate patients subsequently becoming Cases and Controls (a). Si-
milarly, when measured before the administration of the iodinated
contrast medium, urinary levels of transferrrin were significantly higher
in Cases, i.e., in patients who subsequently developed evidence of CIN,
than in Controls who did not. Also, ROC curves were obtained for the
capacity of urinary transferrin to pre-emptively discriminate patients
subsequently becoming Cases and Controls (b). Congruently with the
observations in animal models, sensitive biomarkers of subclinical renal
damage (NAG and NGAL) have no significant predictive capacity in
either clinical setting (Fig. 9). Mean values are not statistically different
between Cases and Controls, and ROC curves show much lower pre-
dictive value than transferrin.
4. Discussion
Overall, our data indicate that an increased urinary excretion of
transferrin is strongly associated to the acquired predisposition to AKI
induced by subnephrotoxic exposure to different nephrotoxins in rats.
Also that in predisposed animals, urinary transferrin tightly correlates
with the severity of the subsequent renal dysfunction triggered by ex-
posure to a second insult that is not toxic to non-predisposed rats. And
finally, that urinary transferrin pre-emptively identifies a fraction of
oncological patients that will develop evidence of nephrotoxicity fol-
lowing treatment with cisplatin or carboplatin, and a fraction of car-
diology patients who will subsequently suffer CIN.
From the existing animal models of acquired predisposition to AKI
[19–21] no common mechanism and biomarker of predisposition had
been previously identified, but only model-specific biomarkers. Inter-
estingly, our present results show that transferrin is a biomarker of
several animal models of predisposition resulting from exposure to di-
verse stimuli, and also of an etiopathologically heterogeneous, clinical
Fig. 5. Increase in urinary transferrin excretion
during the predisposition stage in different
animal models: Representative Western blot
images of urinary transferrin and the corre-
sponding densitometry quantification.
“Increase in urinary transferrin” reflects the
difference between the selected time point and
baseline values (i.e. day zero or week 11, de-
pending on the model). Both time points pre-
ceded the administration of the second (trig-
gering) insult (i.e. subnephrotoxic gentamicin
or CsA). Control animals received saline or
vehicle. Values are expressed as the
mean ± SEM. **, p < 0.01 vs. Control group.
AU, arbitrary units; d, day; w, week; CP, cis-
platin; CsA, cyclosporine; G, gentamicin; UN,
uranyl nitrate.
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condition predisposing to platinum chemotherapy nephrotoxicity.
These facts suggest that a common mechanism may underlie many
forms of predisposition to AKI and, congruently, a common biomarker
could be characterized. In this sense, our study also sheds some light on
the underlying mechanisms of predisposition to AKI identified by ele-
vated urinary transferrin. Transferrin is a 79-kDa plasma protein pro-
duced in the liver, shed to the circulation where it binds one or two
Fe3+ atoms, and therefrom endocytosed by many cell types for Fe de-
livery, through specific plasma membrane receptors (TfR1 and TfR2)
[46,47]. Transferrin is known to be filtered to a certain extent through
the glomerular filtration barrier, and mostly reabsorbed in the proximal
tubule [48]. The luminal membrane of proximal tubule epithelial cells
contains both TfRs and the megalin-cubilin complex, another transport
system known to internalize many molecules including transferrin
[48–50]. Our results from in situ perfused kidneys, and from the maleate
model suggest that the increased levels of urinary transferrin found in
rats predisposed to AKI result from an altered tubular reabsorption. And
these results also indicate that subclinical tubular dysfunction is asso-
ciated, and probably etiologically related, to a common mechanism of
predisposition to AKI underlying several etiologically distinct animal
models. Congruently with this, transferrin identifies the predisposition
caused by nephrotoxins known to accumulate in and affect the proximal
tubules, i.e. gentamicin [51,52], cisplatin [53] and uranyl nitrate [54].
In contrast, the predisposition induced by cyclosporine A is not detected
by transferrin, coinciding with a different mechanism. In fact, cyclos-
porine nephrotoxicity is thought to result from renal vasoconstriction
and altered renal hemodynamics [55].
In agreement with these animal studies, the level of urinary trans-
ferrin identifies a fraction of patients predisposed to the nephrotoxicity
of platinum-based oncological treatments and iodinated contrast media
Fig. 6. Correlation between urinary transferrin excretion during the predisposition stage and the increase in plasma creatinine and urea during the AKI stage. AU:
arbitrary units; R Pearson: Pearson's correlation coefficient.
A.G. Casanova, et al. Biomedicine & Pharmacotherapy 121 (2020) 109684
9
in a non-selected and heterogeneous population. In both cases, thus,
before exposure to the potentially nephrotoxic agent, patients had
individual levels of risk of renal damage produced by a specific but
heterogeneous mix of undetermined factors, unknown to the specialist.
As shown in Fig. 8, according to the ROC curves, the predictive efficacy
of urinary transferrin is higher in the oncology study than in the car-
diology study. Following our own argument, this difference is con-
gruent with the different mechanism of nephrotoxicity of platinated
antineoplastics and iodinated contrast media. Whereas antineoplastics
mainly alter the renal tubules [33], contrasts have both vascular and
hemodynamic effects, and also tubular toxicity [56,57]. In the case of
antineoplastics, transferrin seems to detect more patients because, lo-
gically, subclinical tubular alterations are more likely to predispose to
further tubular damage. Whereas in the case of iodinated contrasts, CIN
may have a more pronounced tubular phenotype in some patients
(those identified by transferrin); and a bolder vascular and hemody-
namic phenotype others (i.e. those not identified by transferrin), who
are less expected to be predisposed (or to a lower extent) by subclinical
tubular alterations (i.e. those inducing the increase in urinary trans-
ferrin).
Altogether, our preclinical and clinical results suggest that elevated
urinary transferrin may be a biomarker resulting from the core of a
common, not yet sufficiently characterized, mechanism of predisposi-
tion to renal damage involving some degree of proximal tubule
Table 2
Correlation between urinary NAG or NGAL excretion during the predisposition
stage and the increase in plasma creatinine and urea during the AKI stage. NAG:
N-acetyl-β-D-glucosaminidase; NGAL: neutrophil gelatinase-associated lipo-







R Pearson p-value R Pearson p-value
Cisplatin model −0.06 0.81 −0.14 0.56
Cyclosporine model −0.05 0.90 −0.06 0.89
Gentamicin model 0.29 0.48 0.48 0.23
Uranyl nitrate model 0.32 0.45 0.75 0.04*
Increase in NGAL
excretion
Cisplatin model −0.10 0.69 −0.15 0.53
Cyclosporine model 0.05 0.91 −0.12 0.78
Gentamicin model 0.53 0.18 0.55 0.16
Uranyl nitrate model 0.57 0.14 0.80 0.017*
* statistically significant difference.
Fig. 7. Representative images of Western blot analysis and the corresponding densitometry quantification of urinary transferrin excretion, a) during the phase of
auto-perfusion with blood and during the Krebs-dextran perfusion phase; and b) before (-30 and -15min) and after (15min) administration of sodium maleate or
saline vehicle. Values are expressed as the mean ± SEM. ***, p < 0.001 vs. 1. AU, arbitrary units.
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subclinical dysfunction, which merits further investigation. We spec-
ulate that a renal damage-predisposing agent activating this mechanism
may totally or partially exhaust the proximal tubule functional reserve.
As a result, when in these circumstances the kidneys are challenged by a
level of exposure to the triggering insult that would have no con-
sequences in non-predisposed kidneys, proximal tubules would be in-
competent to fully reabsorb the ultrafiltrate load, leading to the acti-
vation of the tubuloglomerular feedback mechanism and to a reduction
in GFR, and compromising hydroelectrolytic balance. With this
knowledge, a personalized approach to therapy may be implemented by
selectively monitoring more intensely those patients at high risk of
nephrotoxicity, by individually adjusting treatment and posology, and
by implementing preventive measures to optimize kidney outcomes.
These results provide a step forward and the proof-of-concept for the
clinical application of a conceptually new strategy to manage drug
nephrotoxicity and AKI in a truly preventive and personalized manner,
hitherto impossible to detect and thus impossible to implement in the
clinical practice. This approach may help to minimize acute ne-
phrotoxicity and its long-term sequelae, such as the need for chronic
dialysis [22].
This study poses a base for a larger, multicenter study, as sample
size is a limitation of this study. It also invites to explore the capacity of
urinary transferrin to pre-emptively detect the risk of kidney injury in
other clinical circumstances in which a potentially kidney-injuring in-
sult, treatment or clinical procedure, has a known timeline, and allows
to preventively personalize risk stratification and risk-reducing
Fig. 8. a) Basal and pre-injury urinary levels of transferrin
in samples from Cases and Controls patients in a) oncology
patients treated with platinated antineoplastics (Study 1);
and b) basal urinary levels of transferrin in samples from
Cases and Controls in cardiology patients subject to iodi-
nated contrast media (Study 2). Representative images of
Western blot analysis and its corresponding densitometry
quantification; and evaluation of diagnostic performance
of urinary transferrin through ROC curves and area under
the curves values (95 % CI). Data are expressed as the
mean ± SEM. AU: arbitrary units; AUC, area under the
curve; B, basal; Cr, creatinine; PeI, pre-injury. *,
p < 0.05; **, p < 0.01; ***, p < 0.001 vs. Controls
group.
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strategies. In these situations, anticipation of AKI risk at the individual
level, may help to avoid potentially harmful treatments or procedures
in high risk patients; whereas to use them with confidence (or even at
higher intensity, if necessary) in low risk patients. Finally, urinary
transferrin might also have a diagnostic role in the community for the
monitoring of risk of AKI in the general population through routine
outpatient analysis and in the context of family medicine.
Fig. 9. Urinary levels of NAG and NGAL in basal samples from Case and Control patients, and evaluation of diagnostic performance of urinary transferrin through
ROC curves in a) oncology patients treated with platinated antineoplastics (Study 1); and b) cardiology patients subject to iodinated contrast media (Study 2). Area
under the curve (AUC) values (95 % CI). In left panels, data are expressed as the mean ± SEM. Cr, creatinine; NAG, N-acetyl-β-D-glucosaminidase; NGAL, neutrophil
gelatinase-associated lipocalin.
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